Drug Trial Radar · NCT05610189
Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease
Last checked: Nov 19, 2026Latest source record: Feb 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Dec 15, 2022
Primary completion
Dec 12, 2023
Study completion Dec 17, 2023
Sponsor
- Lead sponsor
- Cerevel Therapeutics, LLCIndustry
- Sponsor type
- Industry
- First posted
- Nov 9, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 45 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of the study is to evaluate the bioequivalence (BE) of tavapadon 15 milligram (mg) tablet to 3x5 mg tablets in participants with Parkinson's disease.
Conditions
- Parkinson Disease
Interventions
TavapadonDrug
Oral tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Plasma Concentration (Cmax) of TavapadonTime frame: Pre-dose and at multiple timepoints post-dose up to Day 28
- Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUCτ) of TavapadonTime frame: Pre-dose and at multiple timepoints post-dose up to Day 28
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Los Alamitos, California
Los Alamitos, California
Hollywood, Florida
Hollywood, Florida
Orlando, Florida
Orlando, Florida
South Miami, Florida
South Miami, Florida
Decatur, Georgia
Decatur, Georgia
Farmington Hills, Michigan
Farmington Hills, Michigan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.